Conference report: Phase III CHECKMATE- 214 shows nivolumab combination with ipilimumab demonstrates continued survival benefit in patients with previously untreated advanced or metastatic renal cell carcinoma

At 42 months, the overall survival rate was 52% for patients treated with nivolumab combination with ipilimumab vs 39% for patients treated with sunitinib alone (HR 0.66, 95% CI 0.55-0.80). Overall response rate was 42% vs 26% for respectively (p=0.0001).

Source:

Biospace Inc.